A panel of five plasma proteins for the early diagnosis of hepatitis B virus-related hepatocellular carcinoma in individuals at risk
A panel of five plasma proteins for the early diagnosis of hepatitis B virus-related hepatocellular carcinoma in individuals at risk
复制标题
一组五种血浆蛋白，用于早期诊断乙型肝炎病毒相关的肝细胞癌高危人群
DOI：
10.1016/j.ebiom.2020.102638
复制
发表时间：
2020-02-01
期刊：
影响因子：
11.1
通讯作者：
Liu, Shanrong
中科院分区：
文献类型：
--
作者：
Cheng, Kai;Shi, Jie;Liu, Shanrong
背景：为提高肝细胞癌（HCC）的早期诊断，需要更有效的诊断生物标志物。一个生物标志物的组合，以区分个人与早期肝癌的风险individual.Methods：在这项研究中的参与者被招募从六家医院在中国。通过文献回顾筛选出19个候选蛋白，并在发现阶段进行病例对照研究，筛选出5个蛋白（P5），构成诊断模型。在训练和验证阶段，测试了P5检测早期HCC的有效性（横断面研究）。最后，一个独立于其他阶段的巢式病例对照研究，以评估P5在临床前诊断HCC.Findings：在2013年2月至2017年6月期间，共招募了1396名参与者。一组5种蛋白质（P5：OPN、GDF15、NSE、TRAP5和OPG）在区分早期HCC与风险组时显示出高诊断准确性，训练阶段、验证队列1和队列2数据集的ADC分别为0.892、0.907和0.852。在预测集中，P5诊断临床前HCC的灵敏度随着时间的推移而增加，从12个月前开始到最终临床诊断的时间（范围，46.15%至86.67%）。解释：P5面板具有筛查HCC高危人群的潜力，可以实现HCC的早期诊断。(C)2020作者由爱思唯尔公司出版
Background: To improve the early diagnosis of hepatocellular carcinoma (HCC), more effective diagnostic biomarkers are needed. A combination of biomarkers is reported to distinguish individuals with early-stage HCC from at-risk individuals.Methods: Participants in this study were recruited from six hospitals in China. Literature review was used to choose 19 candidate proteins, a case-control study in the discovery stage was used to identify five proteins (P5) that constituted a diagnostic model. In the training and validation stages, the effectiveness of P5 for detecting early-stage HCC was tested (cross-sectional study). Finally, a nested case-control study independent of the other stages was set up to evaluate the P5 in the preclinical diagnosis of HCC.Findings: Between February 2013 and June 2017, a total of 1396 participants were recruited. A panel of 5 proteins (P5: OPN, GDF15, NSE, TRAP5 and OPG) showed high diagnostic accuracy when differentiating the early-stage HCC from the at-risk group, with ADCs of 0.892, 0.907 and 0.852 for the training stage, validation cohort 1 and cohort 2 data sets, respectively. In the prediction set, the sensitivity of P5 for diagnosing preclinical HCC increased with time, starting from 12 months before to the time of definitive clinical diagnosis (range, 46.15% to 86.67%).Interpretation: The P5 panel has the potential to screen populations at high risk of developing HCC and can enable the early diagnosis of HCC. (C) 2020 The Authors. Published by Elsevier B.V.